The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of key presentations and posters of interest.
Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver disease. This conversation explores the use of FIB-4 as a front-line tool for primary care. The advocates share their final thoughts on a change they can make in their country in the next 12 months that might extend beyond the country’s borders.
Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation explores patient needs and inputs for trial design and the extent to which they are considered.
Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. The group explores topics ranging from the economics of drug development to the future of digital therapeutics, all centering around the patient perspective.
Does the NICE Draft Guidance and methodology reveal a bad fit between the NICE mode of analysis and wellness-oriented solutions like early NAFLD screening?
Roger Green and Louise Campbell are joined by Dr Kathryn Jack, Professors Ian Rowe and William Alazawi to discuss the recent NICE meeting on use of VCTE in primary care settings. In this conversation, the group explores how to create and train on delivering meaningful test results to patients.
Roger Green and Louise Campbell are joined by Dr Kathryn Jack, Professors Ian Rowe and William Alazawi to investigate the link between socioeconomic status and liver health outcomes. In this episode, the group discusses the challenges of developing accessible pathways and who will administer FibroScan in a community setting.
Roger Green, Louise Campbell, Professor Ian Rowe and Dr Kathryn Jack discuss a process used in the UK called “commissioning through evaluation.” Mid-conversation, Professor William Alazawi joins an investigation into political pressures and metaphorical issues that shape the differences between cancer and liver disease management.
Roger Green and Louise Campbell are joined by Professor Ian Rowe and Dr Kathryn Jack to discuss the recent NICE meeting on use of VCTE in primary care settings. The group explores the dynamic challenges of utilizing FibroScan and other noninvasive tests (NITs) for best practice in community settings.
Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among
